Literature DB >> 18502483

Prostate tissue androgens: history and current clinical relevance.

Leonard S Marks1, Elahe A Mostaghel, Peter S Nelson.   

Abstract

Direct determination of androgen levels in prostate tissue provides a perspective on the organ that is not available via androgen serum levels. The principle prostatic androgens, primarily dihydrotestosterone (DHT) and secondarily testosterone, can be readily assayed in quick-frozen prostate biopsy cores or surgical specimens. Such assays have proved important in establishing (1) that DHT is a permissive factor in BPH pathogenesis, (2) a mechanism for the treatment of BPH, (3) an understanding of prostate cancer chemoprevention, (4) an explanation for the 'escape' of prostate cancer from castration therapy, (5) prostate safety of testosterone replacement therapy, and (6) insights into the cause of racial differences of prostate cancer. Future opportunities include clarification of new drug mechanisms for BPH and prostate cancer, as well as a better understanding of the pathogenesis of both, and as an aid in individual patient management. Determination of prostate tissue androgens may soon transition from research tool to clinical test.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502483      PMCID: PMC7313541          DOI: 10.1016/j.urology.2008.03.033

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  51 in total

Review 1.  Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan.

Authors:  Shalender Bhasin; Atam B Singh; Ricky Phong Mac; Ballentine Carter; Martin I Lee; Glenn R Cunningham
Journal:  J Androl       Date:  2003 May-Jun

2.  The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.

Authors:  J P Weber; J E Oesterling; C A Peters; A W Partin; D W Chan; P C Walsh
Journal:  J Urol       Date:  1989-04       Impact factor: 7.450

3.  The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate.

Authors:  N Bruchovsky; J D Wilson
Journal:  J Biol Chem       Date:  1968-11-25       Impact factor: 5.157

4.  Determination of prostatic androgens in 10 mg of tissue using liquid chromatography-tandem mass spectrometry with charged derivatization.

Authors:  Tatsuya Higashi; Akinori Yamauchi; Kazutake Shimada; Eitetsu Koh; Atsushi Mizokami; Mikio Namiki
Journal:  Anal Bioanal Chem       Date:  2005-05-21       Impact factor: 4.142

5.  Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.

Authors:  Leonard S Marks; Norman A Mazer; Elahe Mostaghel; David L Hess; Frederick J Dorey; Jonathan I Epstein; Robert W Veltri; Danil V Makarov; Alan W Partin; David G Bostwick; Maria Luz Macairan; Peter S Nelson
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

6.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

7.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

8.  Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

Authors:  C B Lazier; L N Thomas; R C Douglas; J P Vessey; R S Rittmaster
Journal:  Prostate       Date:  2004-02-01       Impact factor: 4.104

9.  The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.

Authors:  Atsushi Mizokami; Eitetsu Koh; Hiroshi Fujita; Yuji Maeda; Masayuki Egawa; Kiyoshi Koshida; Seijiro Honma; Evan T Keller; Mikio Namiki
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

10.  Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate.

Authors:  J Geller; J Albert; D Lopez; S Geller; G Niwayama
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

View more
  17 in total

Review 1.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

2.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Meng Sun; Jun Chen; Jiao Yue; Hsing-Jien Kung; Christopher P Evans; Qinghua Zhou; Allen C Gao
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

3.  Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; George G Klee; Michael M Lieber; Steven J Jacobsen
Journal:  Am J Epidemiol       Date:  2011-03-02       Impact factor: 4.897

4.  Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.

Authors:  Stephanie T Page; Daniel W Lin; Elahe A Mostaghel; Brett T Marck; Jonathan L Wright; Jennifer Wu; John K Amory; Peter S Nelson; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

Review 5.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

6.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

7.  New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Yu-Jia Chang; Chin-Ying Chung; Shinichi Yamashita; Lei Li; Soo Ok Lee; Shuyuan Yeh; Chawnshang Chang
Journal:  Am J Pathol       Date:  2012-12-04       Impact factor: 4.307

8.  A novel androgen signalling pathway uses dihydrotestosterone, but not testosterone, to activate the EGF receptor signalling cascade in prostate stromal cells.

Authors:  V L Oliver; K Poulios; S Ventura; J M Haynes
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

9.  Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

Authors:  Azriel Schmidt; Shun-Ichi Harada; Donald B Kimmel; Chang Bai; Fang Chen; Su Jane Rutledge; Robert L Vogel; Angela Scafonas; Michael A Gentile; Pascale V Nantermet; Sheila McElwee-Witmer; Brenda Pennypacker; Patricia Masarachia; Soumya P Sahoo; Yuntae Kim; Robert S Meissner; George D Hartman; Mark E Duggan; Gideon A Rodan; Dwight A Towler; William J Ray
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

10.  Interleukin-6 regulates androgen synthesis in prostate cancer cells.

Authors:  Jae Yeon Chun; Nagalakshmi Nadiminty; Smitha Dutt; Wei Lou; Joy C Yang; Hsing-Jien Kung; Christopher P Evans; Allen C Gao
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.